Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER

SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION

OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number: 000-52445

 

PETLIFE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

8033 Sunset Blvd, Suite 867

Los Angeles, CA 90046

[phone]

(Address, including zip code and telephone number, including area code, of

registrant’s principal executive offices)

 

Common Stock, $0.001 par value

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports

under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)		[X]
Rule 12g-4(a)(2)		[  ]
Rule 12h-3(b)(1)(i)		[  ]
Rule 12h-3(b)(1)(ii)		[  ]
Rule 15d-6		[  ]
Rule 15d-22(b)		[  ]

 

Approximate number of holders of record as of the certification or notice date: 210

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Petlife Pharmaceuticals, Inc. has duly caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

	Petlife Pharmaceuticals, Inc.
Date: October 15, 2019	By:	/s/ Sebastian Serrell-Watts
		Sebastian Serrell-Watts, CEO